Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cancer Science

• Publication date

  2003-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1349-7006.2003.tb01411.xPMID 12708489PMCID PMC11160284
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization

  2002cited by this paper
• Expression of polo‐like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease

  2002cited by this paper
• Comparative Expression of the Mitotic Regulators SAK and PLK in Colorectal Cancer

  2001cited by this paper
• Cell division: Mitotic kinases as regulators of cell division and its checkpoints

  2001cited by this paper
• Polo-like kinase (PLK) expression in endometrial carcinoma.

  2001cited by this paper
• Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage.

  2001cited by this paper
• Polo-like kinase1, a new target for antisense tumor therapy.

  2000cited by this paper
• Centrosomal Kinases, HsAIRK1 and HsAIRK3, are Overexpressed in Primary Colorectal Cancers

  2000cited by this paper
• Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast.

  1999cited by this paper
• Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck.

  1999cited by this paper
• Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers

  1999cited by this paper
• Centrosomes and cancer

  1999cited by this paper
• Prognostic significance of polo-like kinase expression in esophageal carcinoma.

  1999cited by this paper
• Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers

  1999cited by this paper
• Polo-like kinases: positive regulators of cell division from start to finish.

  1998cited by this paper
• Polo-like kinases: a team that plays throughout mitosis.

  1998cited by this paper
• Centrosome defects and genetic instability in malignant tumors.

  1998cited by this paper
• Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity.

  1998cited by this paper
• Polo-like kinase, a novel marker for cellular proliferation.

  1997cited by this paper
• Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase.

  1997cited by this paper
• Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer

  1997cited by this paper
• Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles.

  1995cited by this paper
• Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function

  1995cited by this paper
• Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase.

  1994cited by this paper
• Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5.

  1994cited by this paper
• Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors.

  1994cited by this paper
• A genetic model for colorectal tumorigenesis.

  1990cited by this paper
• Genetic alterations during colorectal-tumor development.

  1988cited by this paper
• TNM Classification of Malignant Tumours

  1987cited by this paper
• The Spread of Rectal Cancer and its Effect on Prognosis

  1958cited by this paper

• Polo-like Kinase 1 Activation Regulates Angiotensin II-Induced Contraction in Pudendal and Small Mesenteric Arteries from Mice

  2025cites this paper
• Structural regulation of PLK1 activity: implications for cell cycle function and drug discovery

  2025cites this paper
• Integrative genomic and single-cell framework identifies druggable targets for colorectal cancer precision therapy

  2025cites this paper
• MLN0905 effectively kills gemcitabine-resistant pancreatic cancer cells by targeting PLK1

  2025cites this paper
• ABCG8-mediated sterol efflux increases cancer cell progression via the LRP6/Wnt/β-catenin signaling pathway in radiotherapy-resistant MDA-MB-231 triple-negative breast cancer cells

  2025cites this paper
• Onvansertib and Navitoclax Combination as a New Therapeutic Option for Mucinous Ovarian Carcinoma

  2025cites this paper
• TUFT1 regulates cancer progression by suppressing centrosome amplification and mitotic spindle multipolarity

  2025cites this paper
• UKLF/PCBP2 axis governs the colorectal cancer development by transcriptionally activating SLC39A4.

  2024cites this paper
• Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling

  2024cites this paper
• PLK1 inhibition leads to mitotic arrest and triggers apoptosis in cholangiocarcinoma cells

  2024cites this paper
• Synergistic two-step inhibition approach using a combination of trametinib and onvansertib in KRAS and TP53-mutated colorectal adenocarcinoma.

  2024cites this paper
• Polo-like Kinase 1 Expression as a Biomarker in Colorectal Cancer: A Retrospective Two-Center Study

  2024cites this paper
• NF-κB-activated oncogene inhibition strategy for cancer gene therapy

  2024cites this paper
• Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality

  2024cites this paper
• PLK1 phosphorylates RhoGDI1 and promotes cancer cell migration and invasion

  2024cites this paper
• Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study

  2024cites this paper
• Polo-like Kinase 1 Predicts Lymph Node Metastasis in Middle Eastern Colorectal Cancer Patients; Its Inhibition Reverses 5-Fu Resistance in Colorectal Cancer Cells

  2024cites this paper
• PLK1 and PARP positively correlate in Middle Eastern breast cancer and their combined inhibition overcomes PARP inhibitor resistance in triple negative breast cancer

  2024cites this paper
• Characteristics and prognostic significance of polo‐like kinase‐1 (PLK1) expression in breast cancer

  2023cites this paper
• RPL27 contributes to colorectal cancer proliferation and stemness via PLK1 signaling

  2023cites this paper
• PLK1 regulating chemoradiotherapy sensitivity of esophageal squamous cell carcinoma through pentose phosphate pathway/ferroptosis.

  2023cites this paper
• Recent Research Progress of PLK1 in Malignant Tumors

  2023cites this paper
• CEBP-β and PLK1 as Potential Mediators of the Breast Cancer/Obesity Crosstalk: In Vitro and In Silico Analyses

  2023cites this paper
• In silico screening of inhibitors for PLK1 from natural sources using SwissDock software for colorectal carcinoma

  2023cites this paper
• The dark side of PLK1: Implications for cancer and genomic instability

  2023cites this paper
• COVID-19 of differing severity: from bulk to single-cell expression data analysis

  2023cites this paper
• Design, synthesis, and biological evaluation of novel molecules as potent inhibitors of PLK1.

  2023cites this paper
• Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma

  2023cites this paper
• Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy

  2023cites this paper
• Establishment of a Necroptosis-Related Prognostic Signature to Reveal Immune Infiltration and Predict Drug Sensitivity in Hepatocellular Carcinoma

  2022cites this paper
• Polo-like kinase 1 as a potential therapeutic target and prognostic factor for various human malignancies: A systematic review and meta-analysis

  2022cites this paper
• Identification of potential functions of polo-like kinase 1 in male reproductive development of the oriental river prawn (Macrobrachium nipponense) by RNA interference analysis

  2022cites this paper
• The kinase PLK1 promotes the development of Kras/Tp53-mutant lung adenocarcinoma through transcriptional activation of the receptor RET

  2022cites this paper
• ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of Polo-like kinase 1 in an m6A dependent manner

  2022cites this paper
• Hyaluronate-coated perfluoroalkyl polyamine prodrugs as bioactive siRNA delivery systems for the treatment of peritoneal cancers.

  2022cites this paper
• New hybrid scaffolds based on ASA/genistein: Synthesis, cytotoxic effect, molecular docking, drug-likeness, and in silico ADME/Tox modeling

  2022cites this paper
• Pan-Cancer Transcriptomic Analysis Identifies PLK1 Crucial for the Tumorigenesis of Clear Cell Renal Cell Carcinoma

  2022cites this paper
• Effect of PEG anchor in PEGylation of folate-modified cationic liposomes with PEG-derivatives on systemic siRNA delivery into the Tumor

  2022cites this paper
• Icaritin inhibits PLK1 to activate DNA damage response in NK/T cell lymphoma and increases sensitivity to GELOX regime

  2022cites this paper
• Cytotoxicity and molecular docking analysis of racemolactone I, a new sesquiterpene lactone isolated from Inula racemosa

  2021cites this paper
• Polo-like kinase 1 (PLK1) signaling in cancer and beyond.

  2021cites this paper
• Structure-based discovery of new polo-like kinase 1 (PLK1) inhibitors as potential anticancer agents via docking-based comparative intermolecular contacts analysis (dbCICA)

  2021cites this paper
• Identi cation of an autophagy-related gene marker for predicting the prognosis in lung adenocarcinoma patients

  2021cites this paper
• Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer

  2021cites this paper
• The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy

  2021cites this paper
• Investigating the Functions of PLK4 in Epigenetic Regulation

  2021cites this paper
• Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification

  2021cites this paper
• Identification of Key Pathways and Genes in SARS-CoV-2 Infecting Human Intestines by Bioinformatics Analysis

  2021cites this paper
• Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.

  2021cites this paper
• Inhibition of the PLK1‐Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer

  2021cites this paper
• Structural investigation of tetrahydropteridin analogues as selective PLK1 inhibitors for treating cancer through combined QSAR techniques, molecular docking, and molecular dynamics simulations

  2021cites this paper
• A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1

  2021cites this paper
• Identification of Hub Genes in Different Stages of Colorectal Cancer through an Integrated Bioinformatics Approach

  2021cites this paper
• Gold Nanoparticles Mediated Drug-Gene Combinational Therapy for Breast Cancer Treatment

  2020cites this paper
• Identification of Core Gene Expression Signature and Key Pathways in Colorectal Cancer

  2020cites this paper
• Potential Drug-Drug Interactions with Combination Volasertib + Itraconazole: A Phase I, Fixed-Sequence Study in Patients with Solid Tumors.

  2020cites this paper
• The dual role of BI 2536, a small-molecule inhibitor that targets PLK1, in induction of apoptosis and attenuation of autophagy in neuroblastoma cells

  2020cites this paper
• Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications

  2020influential citation
• LncRNA TUG1 promotes esophageal cancer development through regulating PLK1 expression by sponging miR-1294

  2020cites this paper
• Polo-like kinase 1 is involved in apoptosis, invasion, and metastasis of pancreatic ductal adenocarcinoma

  2020cites this paper
• Peptidomimetic Polo‐Box‐Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor

  2020cites this paper
• Circular RNAs as miRNA sponges in triple-negative breast cancer: a systematic review

  2020cites this paper
• The CINs of Polo-Like Kinase 1 in Cancer

  2020cites this paper
• Elucidation of PLK1 Linked Biomarkers in Oesophageal Cancer Cell Lines: A Step Towards Novel Signaling Pathways by p53 and PLK1- Linked Functions Crosstalk.

  2020cites this paper
• DeSUMOylase SENP7-Mediated Epithelial Signaling Triggers Intestinal Inflammation via Expansion of Gamma-Delta T Cells

  2019cites this paper
• Inhibition of Oncogenic Kinases: An In Vitro Validated Computational Approach Identified Potential Multi-Target Anticancer Compounds

  2019cites this paper
• Mitotic Exit of Ovarian ancer Cells by Pharmaceutical hibition of the Anaphase-romoting Complex Reduces hromosomal Instability

  2019cites this paper
• OCT4B1 Promoted EMT and Regulated the Self-Renewal of CSCs in CRC: Effects Associated with the Balance of miR-8064/PLK1

  2019cites this paper
• Effect of Cationic Lipid Type in Folate-PEG-Modified Cationic Liposomes on Folate Receptor-Mediated siRNA Transfection in Tumor Cells

  2019cites this paper
• Enhanced polo-like kinase 1 expression in myelodysplastic syndromes

  2019cites this paper
• CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression.

  2019cites this paper
• Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability

  2019cites this paper
• Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition.

  2019cites this paper
• Clinicopathological and prognostic implications of polo-like kinase 1 expression in colorectal cancer: A systematic review and meta-analysis.

  2019cites this paper
• An integrative "omics" approach, for identification of bona fides PLK1 associated biomarker in Oesophgeal adenocarcinoma.

  2019cites this paper
• An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication

  2019cites this paper
• Cell cycle regulation in adrenocortical carcinoma

  2018cites this paper
• Plk1 promotes the migration of human lung adenocarcinoma epithelial cells via STAT3 signaling.

  2018cites this paper
• Molecular Basis of Colorectal Cancer: Tumor Biology

  2018cites this paper
• Combination of PI3K/Akt Pathway Inhibition and Plk1 Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic Carcinoma

  2018cites this paper
• Spindle Assembly Disruption and Cancer Cell Apoptosis with a CLTC-Binding Compound

  2018cites this paper
• Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics

  2018cites this paper
• Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer

  2018cites this paper
• PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells

  2018cites this paper
• The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1.

  2018cites this paper
• Pharmacoinformatics approach for the identification of Polo-like kinase-1 inhibitors from natural sources as anti-cancer agents.

  2018cites this paper
• MECHANISMS OF ENDOCRINOLOGY: Cell cycle regulation in adrenocortical carcinoma.

  2018cites this paper
• Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma.

  2018cites this paper
• Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature

  2018cites this paper
• BI 6727 and gemcitabine combination therapy in pancreatic cancer

  2018cites this paper
• Polo-like kinase 1 expression is suppressed by CCAAT/enhancer-binding protein α to mediate colon carcinoma cell differentiation and apoptosis.

  2017cites this paper
• Evaluation of in vitro and in vivo therapeutic antitumor efficacy of transduction of polo-like kinase 1 and heat shock transcription factor 1 small interfering RNA

  2017cites this paper
• Liposomal delivery of mesoporous silica-coated iron oxide magnetic nanoparticles for theranostic application

  2017cites this paper
• Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia

  2017cites this paper
• Cell cycle regulation and DNA damage response : a record of polo-like kinase 1 activity

  2017cites this paper
• The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis

  2017cites this paper
• Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.

  2017cites this paper
• Polo-Like Kinase 4 (PLK4) Function in Cancer Progression

  2017cites this paper
• Decreased KPNB1 Expression is Induced by PLK1 Inhibition and Leads to Apoptosis in Lung Adenocarcinoma

  2017cites this paper
• Spindle Assembly Checkpoint as a Potential Target in Colorectal Cancer: Current Status and Future Perspectives

  2017cites this paper